Astex Pharmaceuticals, Inc.

282 articles with Astex Pharmaceuticals, Inc.

• 

  Clinical Catch-up from Last Week: June 1-June 7

  6/10/2019

  Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
• 

  Astex Pharma and Otsuka’s Cancer Trial Meets Primary Endpoints

  6/7/2019

  The fixed-dose combination was being evaluated in adults with intermediate and high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

• Astex and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

  6/6/2019

  Astex Pharmaceuticals, Inc. announce top-line results from the ASCERTAIN phase 3 study evaluating cedazuridine and decitabine fixed-dose combination (ASTX727) vs decitabine IV in adults with intermediate and high-risk MDS or CMML.

• Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval

  4/12/2019

  Astex Pharmaceuticals (Astex), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it has received a milestone payment from Janssen Pharmaceutica N.V. (Janssen).

• Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval

  4/12/2019

  Astex Pharmaceuticals (Astex), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it has received a milestone payment from Janssen Pharmaceutica N.V. (Janssen).

• 

  Astex Pharma’s Leukemia Drug Fails Clinical Trial

  7/31/2018

  Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical, indicated their guadecitabine (SGI-110) missed its co-primary endpoints in acute myeloid leukemia (AML).

• Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASTRAL-1 Study of Guadecitabine (SGI-110) in Treatment-Naïve AML Patients Ineligible to Receive Intense Induction Chemotherapy

  7/30/2018

  Astex Pharmaceuticals announce top-line results from the ASTRAL-1 study evaluating the efficacy and safety of guadecitabine (SGI-110) in adults with previously untreated AML who are not eligible for intensive induction chemotherapy.

• Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation

  3/15/2018

  Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.

• Astex Release: Harren Jhoti Receives Lifetime Achievement Award From the UK BioIndustry Association

  1/26/2018

  The Award was presented to Dr. Jhoti by BIA Chair, Dr. Jane Osbourn.

• Astex Pharma Celebrates As Cancer Drug Receives Marketing Approval In Europe

  8/24/2017

• InSysBio LLC Announce Renewal Of Agreement With Astex Pharma

  7/25/2017

• Cambridge-based Astex Pharma Celebrates As Cancer Drug Receives US Marketing Approval

  3/14/2017

• Astex Pharma To Showcase Its Next-Generation Hypomethylating Agents Being Developed For Treatment Of AML/MDS At The 2016 Annual Meeting Of American Society of Hematology

  11/29/2016

• Astex Pharma Joins The Dementia Discovery Fund As A Strategic Investor

  11/21/2016

• Astex Pharma Achieves Milestone On FDA Filing Of New Drug Application (NDA) For LEE011 (Ribociclib) Plus Letrozole As A First-Line Treatment For HR+/HER2- Advanced Breast Cancer

  11/1/2016

• Astex Pharma and Genentech Forge a Clinical Trial Deal for Acute Myeloid Leukemia

  4/20/2016

• Dementia Consortium Signs New Pharma Partner Astex Pharmaceuticals

  10/12/2015

• Astex Pharmaceuticals Announces Orphan Drug Designation For Guadecitabine (SGI-110) In The Treatment Of Acute Myeloid Leukemia

  10/6/2015

• Astex Pharmaceuticals Announces Publication Of Key Clinical Data For Guadecitabine (SGI-110) In The Lancet Oncology

  8/19/2015

• Support For SBC's OI Challenge From Drug Discovery Specialist Astex Pharmaceuticals

  11/11/2014